

Cellmid Ltd

12:00 22 Sep 2016

Cellmid Ltd gets green light for patent in Europe

Cellmid Ltd (ASX:CDY) has been issued a Notice of Allowance by the European Patents Office for a patent similar to already granted patents in Japan and the U.S.

The current European patent is the last in the family enabling extensive coverage of a major area of unmet clinical need.

The patents are related to the prevention of the formation of surgical adhesions, which refers to a build-up of internal scarring following surgery.

The surgical adhesion patents make up one of the eight key patent families which provide the company's dominant intellectual property position.

The post-surgical anti-adhesion market is estimated at \$5 billion globally.

There are no drugs available for preventing surgical adhesions.

Background

Cellmid has two business segments, consumer health and its midkine (MK) portfolio.

Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the MK and FGF5 globally.

Cellmid's consumer health division currently sells hair growth products in Japan and Australia, which were developed using FGF5 related intellectual property.

Cellmid aims to follow in the footsteps of FGF5 by commercialising its MK portfolio.

Cellmid has recently set up dedicated subsidiaries, Lyramid Limited and Kinera Limited as part of its clinical development plan to commercialise its MK antibody assets.

Surgical adhesion

Surgical adhesion is the build-up of internal scarring following surgery.

Whilst adhesions occur in over 95% of abdominal operations, they account for 6% of all readmissions following surgery.

The post-surgical anti-adhesion market is estimated at \$3 billion in the U.S. and \$5 billion globally.

Price: A\$0.5

Market Cap: A\$28.46M

1 Year Share Price Graph



Share Information

Code: CDY

Listing: ASX

52 week High Low
0.8p 0.35p

Sector: Pharma & Biotech

Website: www.cellmid.com.au

Company Synopsis:

Cellmid Ltd (ASX:CDY) is listed on the Australian Securities Exchange.

Author:

Proactive Investors Australia

+61 (0)2 9280 0700

action@proactiveinvestors.com.au

There are no drugs available for preventing surgical adhesions.

Current treatment

Currently, surgical adhesion is most frequently treated by further surgery to sever the adhesions.

However, around 85% of the time this simply results in more adhesions.

The leading method for preventing abdominal surgical adhesions is insertion of bio-absorbable barriers during surgery.

This procedure is often ineffective, relies on surgeons being trained in the proper use of the barriers and it extends operating time and associated costs and risks entailed with this.

Commercialising a new treatment

Lynamid is currently preparing its anti-MK antibody program for first-in-class clinical trials.

One of the objectives of the trial is to demonstrate that MK can be a safe therapeutic target.

Evidence of safety of an anti-MK agent could open up opportunities for a number of pipeline products due to the strong intellectual property position Lynamid holds around this novel disease target.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither

such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.